| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:Compound 2389988-38-7
CAS:2389988-38-7
Package:5mg;10mg;25mg
|
1H-Purine-6,8-dione, 2-amino-7,9-dihydro-7-(4-hydroxy-2-butyn-1-yl)-9-β-D-xylofuranosyl- manufacturers
|
| | 1H-Purine-6,8-dione, 2-amino-7,9-dihydro-7-(4-hydroxy-2-butyn-1-yl)-9-β-D-xylofuranosyl- Basic information |
| | 1H-Purine-6,8-dione, 2-amino-7,9-dihydro-7-(4-hydroxy-2-butyn-1-yl)-9-β-D-xylofuranosyl- Chemical Properties |
| Boiling point | 691.9±65.0 °C(Predicted) | | density | 1.92±0.1 g/cm3(Predicted) | | pka | 12.98±0.10(Predicted) |
| | 1H-Purine-6,8-dione, 2-amino-7,9-dihydro-7-(4-hydroxy-2-butyn-1-yl)-9-β-D-xylofuranosyl- Usage And Synthesis |
| Uses | TLR7 agonist 9 (compound 10) is an aonist of TLR7. TLR7 agonist 9 can be used for research of cancer and infectious disease[1]. TLR7 agonist 9 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | | IC 50 | TLR7 | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005
[2] Webber Stephen E, et al. TLR7 agonists for treatment of cancer and infectious disease. World Intellectual Property Organization, WO2019226977 A1. 2019-11-28. |
| | 1H-Purine-6,8-dione, 2-amino-7,9-dihydro-7-(4-hydroxy-2-butyn-1-yl)-9-β-D-xylofuranosyl- Preparation Products And Raw materials |
|